Hadieh Eslampanah/LinkedIn
May 27, 2025, 07:39
Hadieh Eslampanah: MAHAK and Cancer Genomics Consortium Sign Agreement to Advance Pediatric Cancer Care
Hadieh Eslampanah, Director of International Development and Communications Department at MAHAK Pediatric Cancer Treatment and Research Center, shared a post on LinkedIn:
“Today marked a major milestone with the signing of an agreement between Cancer Genomics Consortium icgcs, and MAHAK Pediatric Cancer Treatment and Research Center (MPCTRC), with the presence of Prof. Farhood; the founder of Genetic Science in Iran. At the Porf. Parvaneh Vosough memorial ceremony, MAHAK CEO Arasb Ahmadian and Prof. Farhood signed the agreement as a step forward in pediatric cancer treatment.
This collaboration opens up significant opportunities by combining expertise and resources, towards advancing targeted therapy and personalized medicine, genomics and bimolecular database analysis. It is a testament to Prof. Vossough’s vision, a future where every child receives the best possible care through the power of modern science and unwavering service.
It is a great pleasure to be part of MAHAK’s ongoing and forward- thinking approach, and believe this collaboration truly embodies the promise of more precise, effective, and targeted treatments for children with cancer, and bringing new hope for families in their most challenging moments.”
More posts featuring Hadieh Eslampanah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 16:50
May 29, 2025, 14:15